JP7797421B2 - フタラジノン化合物、並びにその調製方法及びその医薬用途 - Google Patents

フタラジノン化合物、並びにその調製方法及びその医薬用途

Info

Publication number
JP7797421B2
JP7797421B2 JP2022576009A JP2022576009A JP7797421B2 JP 7797421 B2 JP7797421 B2 JP 7797421B2 JP 2022576009 A JP2022576009 A JP 2022576009A JP 2022576009 A JP2022576009 A JP 2022576009A JP 7797421 B2 JP7797421 B2 JP 7797421B2
Authority
JP
Japan
Prior art keywords
mmol
alkyl
room temperature
stirred
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022576009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531390A (ja
JP2023531390A5 (https=
Inventor
ルゥ，ホンフー
シン，ウェイチャン
ルブ，ヨンツオン
チー，バオジアン
ペン，ジアンビヤオ
グオ，ハイビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jeyou Pharmaceutical Co Ltd
Original Assignee
Shanghai Jeyou Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jeyou Pharmaceutical Co Ltd filed Critical Shanghai Jeyou Pharmaceutical Co Ltd
Publication of JP2023531390A publication Critical patent/JP2023531390A/ja
Publication of JP2023531390A5 publication Critical patent/JP2023531390A5/ja
Priority to JP2025277389A priority Critical patent/JP2026053536A/ja
Application granted granted Critical
Publication of JP7797421B2 publication Critical patent/JP7797421B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022576009A 2020-06-12 2021-06-11 フタラジノン化合物、並びにその調製方法及びその医薬用途 Active JP7797421B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025277389A JP2026053536A (ja) 2020-06-12 2025-12-23 フタラジノン化合物、並びにその調製方法及びその医薬用途

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202010536221.6 2020-06-12
CN202010536221 2020-06-12
CN202011147078.8 2020-10-23
CN202011147078 2020-10-23
CN202011261665.X 2020-11-12
CN202011261665 2020-11-12
CN202110485680 2021-04-30
CN202110485680.0 2021-04-30
CN202110614030.1 2021-06-02
CN202110614030 2021-06-02
PCT/CN2021/099654 WO2021249534A1 (zh) 2020-06-12 2021-06-11 酞嗪酮类化合物及其制备方法和医药用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025277389A Division JP2026053536A (ja) 2020-06-12 2025-12-23 フタラジノン化合物、並びにその調製方法及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2023531390A JP2023531390A (ja) 2023-07-24
JP2023531390A5 JP2023531390A5 (https=) 2024-06-19
JP7797421B2 true JP7797421B2 (ja) 2026-01-13

Family

ID=78846889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022576009A Active JP7797421B2 (ja) 2020-06-12 2021-06-11 フタラジノン化合物、並びにその調製方法及びその医薬用途
JP2025277389A Pending JP2026053536A (ja) 2020-06-12 2025-12-23 フタラジノン化合物、並びにその調製方法及びその医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025277389A Pending JP2026053536A (ja) 2020-06-12 2025-12-23 フタラジノン化合物、並びにその調製方法及びその医薬用途

Country Status (18)

Country Link
US (3) US20230131252A1 (https=)
EP (1) EP4166550A4 (https=)
JP (2) JP7797421B2 (https=)
KR (1) KR20230024328A (https=)
CN (2) CN113801098B (https=)
AU (1) AU2021286738A1 (https=)
BR (1) BR112022025057A2 (https=)
CA (1) CA3186981A1 (https=)
CL (1) CL2022003472A1 (https=)
CO (1) CO2022017802A2 (https=)
CR (1) CR20230007A (https=)
IL (1) IL298962A (https=)
MX (1) MX2022015562A (https=)
PE (1) PE20230610A1 (https=)
PH (1) PH12023550018A1 (https=)
SA (1) SA522441725B1 (https=)
TW (1) TWI781651B (https=)
WO (1) WO2021249534A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN114829342A (zh) 2019-12-23 2022-07-29 上海济煜医药科技有限公司 一种蛋白降解剂化合物的制备方法和应用
JP2023520916A (ja) * 2020-04-08 2023-05-22 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
CR20230007A (es) * 2020-06-12 2023-06-01 Shanghai Jemincare Pharmaceuticals Co Ltd Compuesto de ftalazinona, y método de preparación y uso médico de este.
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
JP2024519628A (ja) * 2021-05-26 2024-05-21 イノキュア セラピューティクス インコーポレイテッド ピペリジンジオン誘導体
KR102474999B1 (ko) * 2021-05-26 2022-12-07 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
TW202321219A (zh) 2021-08-11 2023-06-01 大陸商四川海思科製藥有限公司 雜環衍生物及其組合物和藥學上的應用
WO2024054953A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024054952A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
EP4624472A1 (en) * 2022-11-22 2025-10-01 Innocure Therapeutics, Inc. Degrader including novel c-met protein ligand and pharmaceutical composition including same
KR20240076746A (ko) * 2022-11-22 2024-05-30 주식회사 이노큐어테라퓨틱스 Brd 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
KR20240075764A (ko) * 2022-11-22 2024-05-29 주식회사 이노큐어테라퓨틱스 cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
CN116655591B (zh) * 2023-06-05 2024-11-08 中国人民解放军军事科学院军事医学研究院 3,4-二氢酞嗪-1（2h）-酮类衍生物及制备方法和用途
CN121773112A (zh) 2023-08-17 2026-03-31 海思科医药集团股份有限公司 一种氰基芳香环衍生物及其在医药上的应用
WO2025062330A1 (en) 2023-09-20 2025-03-27 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
CN120025333A (zh) * 2023-11-22 2025-05-23 广东东阳光药业股份有限公司 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途
WO2025193849A1 (en) 2024-03-13 2025-09-18 Genentech, Inc. Polymorphs of ar-degraders
WO2025193851A1 (en) 2024-03-13 2025-09-18 Genentech, Inc. Process for making enantiomers of ar-degraders
WO2025226797A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Kred catalyzed ketoreduction of a cyclobutanone carbamic ester
US12169941B1 (en) 2024-06-13 2024-12-17 Rapsodo Pte. Ltd. System and method for determining a position an object crosses a target plane

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502385A (ja) 1997-05-30 2002-01-22 シエーリング アクチエンゲゼルシヤフト ゲスターゲン及びアンドロゲン混合作用を有する非ステロイド系（複素）環式置換アシルアニリド
JP2018502925A (ja) 2015-01-20 2018-02-01 アルビナス インコーポレイテッド ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN110194762A (zh) 2018-02-27 2019-09-03 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途
JP2019530715A (ja) 2016-10-11 2019-10-24 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． アンドロゲン受容体の標的分解のための化合物および方法
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
CA3042297A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN112390852B (zh) 2019-08-14 2022-10-18 上海济煜医药科技有限公司 作为蛋白降解剂的化合物及其制备方法和应用
CN112457367B (zh) 2019-09-06 2022-08-23 上海济煜医药科技有限公司 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN112457366B (zh) 2019-09-06 2024-03-19 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和应用
CN118930604A (zh) 2019-09-29 2024-11-12 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及包含其的药物组合物和应用
CN114829342A (zh) 2019-12-23 2022-07-29 上海济煜医药科技有限公司 一种蛋白降解剂化合物的制备方法和应用
CN113582974B (zh) 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
CR20230007A (es) * 2020-06-12 2023-06-01 Shanghai Jemincare Pharmaceuticals Co Ltd Compuesto de ftalazinona, y método de preparación y uso médico de este.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502385A (ja) 1997-05-30 2002-01-22 シエーリング アクチエンゲゼルシヤフト ゲスターゲン及びアンドロゲン混合作用を有する非ステロイド系（複素）環式置換アシルアニリド
JP2018502925A (ja) 2015-01-20 2018-02-01 アルビナス インコーポレイテッド ターゲティングされたアンドロゲン受容体分解のための化合物および方法
JP2019530715A (ja) 2016-10-11 2019-10-24 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． アンドロゲン受容体の標的分解のための化合物および方法
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
CN110194762A (zh) 2018-02-27 2019-09-03 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
大岡 伸通 他，新しい低分子薬の創薬モダリティPROTAC，ファルマシア，2020年01月01日，第56巻, 第1号，pp. 41-45，DOI: 10.14894/faruawpsj.56.1_41，公開日:2020/01/01
天児 由佳，ＰＲＯＴＡＣｓ－ユビキチンリガーゼをハイジャックしてタンパク質を分解するキメラ分子－，有機合成化学協会誌，2018年04月01日，第76巻, 第4号，pp. 358-359

Also Published As

Publication number Publication date
JP2023531390A (ja) 2023-07-24
CO2022017802A2 (es) 2023-03-17
US20230242510A1 (en) 2023-08-03
CN116082311A (zh) 2023-05-09
CN113801098B (zh) 2023-05-30
IL298962A (en) 2023-02-01
PE20230610A1 (es) 2023-04-13
CR20230007A (es) 2023-06-01
US12234223B2 (en) 2025-02-25
US20240400540A1 (en) 2024-12-05
WO2021249534A1 (zh) 2021-12-16
AU2021286738A1 (en) 2023-01-19
EP4166550A4 (en) 2024-08-07
CL2022003472A1 (es) 2023-06-02
TW202146400A (zh) 2021-12-16
EP4166550A1 (en) 2023-04-19
CN116082311B (zh) 2025-04-25
PH12023550018A1 (en) 2024-03-11
SA522441725B1 (ar) 2024-08-11
KR20230024328A (ko) 2023-02-20
MX2022015562A (es) 2023-01-30
US11767312B2 (en) 2023-09-26
CN113801098A (zh) 2021-12-17
TWI781651B (zh) 2022-10-21
BR112022025057A2 (pt) 2023-01-31
CA3186981A1 (en) 2021-12-16
JP2026053536A (ja) 2026-03-25
US20230131252A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
JP7797421B2 (ja) フタラジノン化合物、並びにその調製方法及びその医薬用途
JP7791087B2 (ja) タンパク質分解剤化合物の製造方法及び使用
CN121843944A (zh) 大环化合物及其抗体-药物偶联物
TWI846774B (zh) 作為免疫調節的芳環衍生物及其製備方法和應用
CN112457366B (zh) 作为蛋白降解剂的并环类化合物及其制备方法和应用
JP2022550427A (ja) Ｐｄ－１／ｐｄ－ｌ１小分子阻害剤としての化合物及びその使用
US12129246B1 (en) Hydroquinazoline derivatives for the treatment of a disease or disorder
EP3909583A1 (en) Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity
RU2844016C1 (ru) Фталазиноновое соединение, способ его получения и его медицинское применение
TW202540127A (zh) 一種吡咯［２，３－ｂ］并吡啶衍生物及其製備方法和用途
HK40092053A (en) Phthalazinone compound, and preparation method therefor and medical use thereof
EP3395798A1 (en) Non-aromatic heterocyclic derivative having mgat2 inhibitory activity
KR20240110040A (ko) 질환 또는 장애 치료용 나프티리디논 유도체
TW202233626A (zh) 三氮唑類三并環衍生物及其製備方法和應用
HK40104808A (zh) 作为蛋白降解剂的并环类化合物及其制备方法和用途
WO2025120242A1 (en) Chimeric radiopharmaceuticals targeting the proton sensing receptor gpr4
HK40114563A (zh) 作为蛋白降解剂杂环类化合物及包含其的药物组合物和应用
WO2026041109A1 (zh) 成纤维细胞活化蛋白抑制剂及其用途
EA047485B1 (ru) Соединение, представляющее собой средство для разрушения белка, и его применения для лечения рака и предупреждения или лечения болезни кеннеди
TW202543607A (zh) 介白素１７ａ抑制劑及其用途
WO2025167951A1 (zh) 一种成纤维细胞活化蛋白抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251224

R150 Certificate of patent or registration of utility model

Ref document number: 7797421

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150